DiaSorin (OTCMKTS:DSRLF) Shares Gap Up – Should You Buy?

DiaSorin S.p.A. (OTCMKTS:DSRLF) shares gapped up prior to trading on Friday . The stock had previously closed at $74.25, but opened at $81.90. DiaSorin shares last traded at $80.25, with a volume of 3,100 shares.

Wall Street Analysts Forecast Growth

DSRLF has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft downgraded shares of DiaSorin from a “hold” rating to a “sell” rating in a report on Wednesday, June 17th. BNP Paribas Exane lowered shares of DiaSorin from a “neutral” rating to an “underperform” rating in a research report on Tuesday. Piper Sandler began coverage on shares of DiaSorin in a research note on Thursday, June 11th. They set a “neutral” rating on the stock. Zacks Research upgraded DiaSorin to a “hold” rating in a research note on Tuesday, May 12th. Finally, UBS Group cut DiaSorin from a “buy” rating to a “neutral” rating in a research report on Thursday, April 9th. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, DiaSorin presently has an average rating of “Hold”.

DiaSorin Trading Down 4.6%

The business’s 50-day moving average price is $74.70 and its 200 day moving average price is $76.22.

About DiaSorin

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.